Navigation Links
ACT Obtains Exclusive License for Hemangioblast Technology in North America
Date:7/21/2011

r of ACT.  "Hemangioblasts can be used to provide transfusable blood components, such as red blood cells and platelets, as well as cells capable of affecting vascular repair.  We hope that these programs will eventually help address the critical care shortage of blood for emergency situations. In addition, our preclinical research has shown the ability of hemangioblast-derived cells to repair vascular damage when administered systemically, offering potential therapeutic uses to treat vascular ischemic damage, ischemia-reperfusion injury, diabetic vascular disease and peripheral artery disease (PAD), which represent the leading causes of death and/or disability worldwide.  Indeed, in preclinical studies, these cells quickly repaired vascular damage, cutting the death rate after a heart attack in half and restoring the blood flow to ischemic limbs that might otherwise have required amputation."

The proprietary hemangioblast technology developed by SCRMI and ACT is uniquely well-suited for developing stem cell-based therapies because they are highly expandable and can consistently and reproducibly give rise to various cells of the hematopoietic (blood) and endothelial (vascular) lineages.  Strong clinical demand for donated platelets, for example, has stimulated interest in generating renewable sources of transfusable platelets.  In recent scientific publications, SCRMI scientists demonstrated that it is feasible to generate functional megakaryocytes and platelets from hESCs on a large scale.  The hESC-platelets displayed features that were indistinguishable from those of normal blood platelets, and participated in both clot formation and retraction in-vitro.

In September of last year, Dr. Lanza and Kwang-Soo Kim, Ph.D. (Harvard University/McLean Hospital and CHA Stem Cell Institute),

SOURCE Advanced Cell Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
3. Occlutech Obtains Favourable Court Ruling in Patent Litigation in The Hague Against AGA Medical
4. China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
5. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
6. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
7. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
8. Occlutech Obtains Favourable Ruling in Proceedings Initiated by AGA Medical
9. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
10. China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief
11. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014 Cirrascale Corporation ®, ... and rackmount computing infrastructure, today announced it will ... throughout its GPU-enabled blade server and high-performance workstation ... latest proprietary 80-lane Gen3 PCIe switch-enabled risers, the ... K80 dual-GPU accelerator cards in a single blade, ...
(Date:11/18/2014)... 18, 2014 American Process Inc. ... formed a partnership with researchers at Georgia Institute ... Technology, and the USDA’s Forest Products Laboratory to ... nanocellulose. Nanocellulose is a rapidly emerging high performance ... project is to replace heavy steel structures within ...
(Date:11/18/2014)... Nov. 18, 2014 PDL BioPharma, Inc. (PDL) ... connection with the acquisition of Durata Therapeutics, Inc. by ... with the termination of PDL,s credit agreement with Durata, ... of $40 million, accrued interest, and prepayment and change ... a structured financing transaction with Durata in which PDL ...
(Date:11/17/2014)... The new METTLER TOLEDO White Paper " Traceability ... becoming the first calibration laboratory in the world ... the microgram range. National Metrology Institutes (NMI's), private ... in nanotechnology applications will benefit from understanding the ... weights in the range of 0.05 mg to ...
Breaking Biology Technology:Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2
... Jan. 31, 2011 Fox Chase Cancer Center , one ... the posting of clinical outcomes data to its website ... seek cancer care.  This initiative follows on a survey Fox Chase ... success rates as the factor that would be the most ...
... China-Biotics, Inc. ("China-Biotics", the "Company") (Nasdaq: ... of probiotics products in China, today announced it will ... p.m. Beijing Time on Wednesday, February 9, 2011, to ... for the period ended December 31, 2010. ...
... Mass., Jan. 31, 2011 Haemonetics Corporation (NYSE: HAE ... net income of $19.7 million, up 8%, and earnings per share ... third quarter net income was $ 22.6 million, up 21%, and ... revenue was up 6%, adjusted net income was up 21%, and ...
Cached Biology Technology:Fox Chase Cancer Center Publishes Clinical Outcomes for Patient Use 2Fox Chase Cancer Center Publishes Clinical Outcomes for Patient Use 3China-Biotics to Report Fiscal Year 2011 Third Quarter Financial Results on February 9 2Haemonetics Reports Third Quarter of Fiscal 11 2Haemonetics Reports Third Quarter of Fiscal 11 3Haemonetics Reports Third Quarter of Fiscal 11 4Haemonetics Reports Third Quarter of Fiscal 11 5Haemonetics Reports Third Quarter of Fiscal 11 6Haemonetics Reports Third Quarter of Fiscal 11 7Haemonetics Reports Third Quarter of Fiscal 11 8Haemonetics Reports Third Quarter of Fiscal 11 9Haemonetics Reports Third Quarter of Fiscal 11 10Haemonetics Reports Third Quarter of Fiscal 11 11Haemonetics Reports Third Quarter of Fiscal 11 12Haemonetics Reports Third Quarter of Fiscal 11 13
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
(Date:11/5/2014)... RENO – Kelly Redmond has dedicated his career ... knowledge to a general audience. , As deputy ... Climate Center at Nevada,s Desert Research Institute, Redmond ... the management, application and dissemination of climate data ... Annual Fall Meeting in San Francisco on December ...
(Date:11/4/2014)... SALT LAKE CITY, Nov. 5, 2014 – University of ... uses enzymes to help jet fuel produce electricity without ... can be used to power portable electronics, off-grid power ... appears online today in the American Chemical Society journal ... into electricity through a chemical reaction between a fuel ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Jet-fueled electricity at room temperature 2
... 2012 The Phoenix Community Alliance (PCA) will honor ... Institute (TGen), with its most prestigious award. Dr. ... Award for his work in improving the lives of ... such as Alzheimer,s, diabetes and many types of cancer. ...
... The National Institutes of Health has awarded The Scripps ... pathway in the development and maintenance of B-cell lymphoma, a ... normal disease fighting cells into cancers. The disease affects immune ... blood cells. John Cleveland, PhD, chair of the ...
... MD FASEB MARC (Maximizing Access to Research Careers) ... 2012 American Society for Clinical Investigation/Association of American Physicians ... 2012. These awards are meant to promote the ... the mainstream of the basic science community and to ...
Cached Biology News:Phoenix Community Alliance honors TGen's Dr. Jeffrey Trent 2Scientists win $2 million to study new pathway in development and maintenance of lymphoma 2
... configured specifically for pharmaceutical powder packaging, ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ... strong, rigid surface without external bracing. ...
... sensitive reagent for the detection of inorganic ... of recombinant E. coli phosphate-binding protein labeled ... to changes in its environment.How it worksBinding ... rapid and tight (Kd ~ 0.1 M), ...
... This benchtop ductless exhaust hood ... allowing safe indoor release of exhaust. ... contaminants. Over 28" of vertical clearance ... glassware. Includes polypropylene spill tray; options ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Biology Products: